June 27th, 2013--(Ref: Business Wire)--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) today announced that it has received a $10 million payment from Takeda Pharmaceutical Company Limited (Takeda), pursuant to the existing collaboration and license agreement between SPI and Takeda. The milestone payment was triggered by the commercial launch of AMITIZA® (lubiprostone) (24 mcg daily) in the United States for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain.
This is the third indication for AMITIZA, AMITIZA is the World's First and Only Oral Medication Approved for Treatment of Opioid-Induced Constipation in Adults with Chronic, Non-cancer Pain, AMITIZA is also approved in the U.S. for the treatment of chronic idiopathic constipation (CIC) in adults (24 mcg twice daily) and irritable bowel syndrome with constipation (IBS-C) in adult women (8 mcg twice daily).
This is the third indication for AMITIZA, AMITIZA is the World's First and Only Oral Medication Approved for Treatment of Opioid-Induced Constipation in Adults with Chronic, Non-cancer Pain, AMITIZA is also approved in the U.S. for the treatment of chronic idiopathic constipation (CIC) in adults (24 mcg twice daily) and irritable bowel syndrome with constipation (IBS-C) in adult women (8 mcg twice daily).